February 13, 2019
The Ministry of Health, Labor and Welfare (MHLW) on February 12 ordered label revisions related to adverse reactions for a batch of drugs including major PD-1 inhibitors Opdivo (nivolumab) and Keytruda (pembrolizumab) , AbbVie’s hepatitis C drug Maviret (glecaprevir +...read more